From: The captopril challenge test for diagnosing primary Aldosteronism in a Chinese population
Ā | APA and IHA | PH and NC | ||
---|---|---|---|---|
Below median (nā=ā54) | Above median (nā=ā53) | Below median (nā=ā102) | Above median (nā=ā101) | |
Urine sodium (mmol/24āh) | 106.3āĀ±ā30.0 | 247.6āĀ±ā76.7A | 109.4āĀ±ā27.7 | 205.5āĀ±ā41.5A |
Pre-PAC (ng/dl) | 17.7āĀ±ā5.9 | 17.4āĀ±ā5.0 | 13.6āĀ±ā4.0 | 13.4āĀ±ā4.2 |
Pre-PRA (ng/ml.h) | 0.20 (0.048~0.42) | 0.23 (0.065~0.35) | 2.2 (0.96~3.7) | 2.3 (1.2~3.7) |
Pre-ARR | 63.1 (45.1~300.4) | 81.5 (48.0~165.2) | 6.8 (3.7~13.1) | 5.9 (3.5~10.1) |
Post-PAC (ng/dl) | 17.2āĀ±ā5.7 | 16.4āĀ±ā5.0 | 12.1āĀ±ā4.0 | 12.2āĀ±ā4.3 |
Post-PRA (ng/ml.h) | 0.28 (0.050~0.62) | 0.31 (0.18~0.49) | 3.4 (1.6~6.1) | 3.0 (1.8~5.0) |
Post-ARR | 50.1 (28.5~223.3) | 52.0 (32.1~89.9) | 3.1 (1.9~7.2) | 3.7 (2.2~6.9) |
PAC suppression percentage (%) | 3.7 (ā8.1~11.8) | 3.4 (ā6.1~13.3) | 12.9 (ā0.73~20.3) | 7.9 (ā3.0~21.9) |
PRA incretion percentage (%) | 25.1 (ā21.3~102.3) | 50.5 (0.0~129.0) | 55.0 (9.3~158.0) | 53.0 (10.1~112.1) |